Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2012

01.09.2012 | Breast Oncology

The Impact of Obesity on Breast Cancer: A Retrospective Review

verfasst von: Danielle J. Haakinson, MD, Steven G. Leeds, MD, Amylou C. Dueck, PhD, Richard J. Gray, MD, Nabil Wasif, MD, Chee-Chee H. Stucky, MD, Donald W. Northfelt, MD, Heidi A. Apsey, CNP, Barbara Pockaj, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity has been linked to many adverse health consequences, including breast cancer; however, the impact on clinical presentation, tumor characteristics, and survival outcomes has yet to be clearly defined.

Methods

Retrospective review of a prospectively collected database of patients treated at a single institution for invasive breast cancer from 2000–2008 comparing two groups: nonobese (body mass index of <30) and obese (body mass index of ≥30) patients. Continuous variables, categorical variables, and survival data were analyzed.

Results

Of 1352 total patients, 76% were classified as nonobese and 24% were obese. When comparing age, obese patients presented less frequently than nonobese patients <50 years old (10% vs. 90%), and when comparing patients >50 years old (18% vs. 82%, P = 0.0019). Obese patients were more likely to present with disease detected by imaging when compared to nonobese patients (67% vs. 56%, P = 0.0006). Obese patients had larger tumors (1.7 cm vs. 1.4 cm, P < 0.001) and higher rates of lymph node (LN) metastases (31% vs. 25%, P = 0.026). On multivariate analysis, obesity was associated with nonpalpable tumors, larger tumors, a higher incidence of LN metastasis, lower incidence of Her2 positivity, lower incidence of multifocality, and less likely to undergo reconstruction after mastectomy.

Conclusions

Obese patients clinically present at older ages with mammographically detected breast cancer at more advanced stages than nonobese patients. Strategies to encourage screening among the obese patient population are important.
Literatur
1.
Zurück zum Zitat Jernal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96.CrossRef Jernal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96.CrossRef
3.
Zurück zum Zitat Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States 2000. JAMA. 2004;291:1238–45.PubMedCrossRef Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States 2000. JAMA. 2004;291:1238–45.PubMedCrossRef
4.
Zurück zum Zitat Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Correction: actual causes of death in the United States 2000. JAMA. 2005;293:293–4.PubMedCrossRef Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Correction: actual causes of death in the United States 2000. JAMA. 2005;293:293–4.PubMedCrossRef
5.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmod K, Thun MJ. Overweight, obesity, and mortality from cancer in a retrospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmod K, Thun MJ. Overweight, obesity, and mortality from cancer in a retrospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef
6.
Zurück zum Zitat Guh DP, Zhang W, Bansback N, Amarsi Z, Birminghas CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.PubMedCrossRef Guh DP, Zhang W, Bansback N, Amarsi Z, Birminghas CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.PubMedCrossRef
7.
Zurück zum Zitat Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997;216:28–43.PubMed Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997;216:28–43.PubMed
8.
Zurück zum Zitat Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4:157–73.PubMedCrossRef Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4:157–73.PubMedCrossRef
9.
Zurück zum Zitat Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.PubMedCrossRef Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.PubMedCrossRef
10.
Zurück zum Zitat Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004;13:85–92.PubMedCrossRef Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004;13:85–92.PubMedCrossRef
11.
Zurück zum Zitat Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002;98:279–83.PubMedCrossRef Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002;98:279–83.PubMedCrossRef
12.
Zurück zum Zitat Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008;111:329–42.PubMedCrossRef Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008;111:329–42.PubMedCrossRef
13.
Zurück zum Zitat Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG. 2006;113:1160–6.PubMedCrossRef Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG. 2006;113:1160–6.PubMedCrossRef
14.
Zurück zum Zitat Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early stage breast cancer. Arch Surg. 2004;139:954–8.PubMedCrossRef Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early stage breast cancer. Arch Surg. 2004;139:954–8.PubMedCrossRef
15.
Zurück zum Zitat Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267–73.PubMedCrossRef Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267–73.PubMedCrossRef
16.
Zurück zum Zitat Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;109:389–95.PubMedCrossRef Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;109:389–95.PubMedCrossRef
17.
Zurück zum Zitat Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.PubMedCrossRef Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.PubMedCrossRef
18.
Zurück zum Zitat Cleary MP, Grossmann ME. Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150:2537–42.PubMedCrossRef Cleary MP, Grossmann ME. Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150:2537–42.PubMedCrossRef
19.
Zurück zum Zitat Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720–9.PubMedCrossRef Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720–9.PubMedCrossRef
20.
Zurück zum Zitat Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17:2078–86.PubMedCrossRef Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17:2078–86.PubMedCrossRef
21.
Zurück zum Zitat Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319–24.PubMedCrossRef Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319–24.PubMedCrossRef
22.
Zurück zum Zitat Feigelson HS, Patel AV, Teras LR, Gansler TS, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006;107:12–21.PubMedCrossRef Feigelson HS, Patel AV, Teras LR, Gansler TS, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006;107:12–21.PubMedCrossRef
23.
Zurück zum Zitat Gillespie EF, Sorbero ME, Hanauer DA, et al. Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol. 2010;17:752–9.PubMedCrossRef Gillespie EF, Sorbero ME, Hanauer DA, et al. Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol. 2010;17:752–9.PubMedCrossRef
24.
Zurück zum Zitat Deglise C, Bouchardy C, Burri M, et al. Impact of obesity on the diagnosis and treatment of breast cancer. Breast Cancer Res Treat. 2010;120:185–93.PubMedCrossRef Deglise C, Bouchardy C, Burri M, et al. Impact of obesity on the diagnosis and treatment of breast cancer. Breast Cancer Res Treat. 2010;120:185–93.PubMedCrossRef
25.
Zurück zum Zitat Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006;119:1683–9.PubMedCrossRef Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006;119:1683–9.PubMedCrossRef
26.
Zurück zum Zitat Colditz GA, Rosner BA, Chen WY, Homes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96:218–28.PubMedCrossRef Colditz GA, Rosner BA, Chen WY, Homes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96:218–28.PubMedCrossRef
28.
Zurück zum Zitat Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;(June):457–81. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;(June):457–81.
29.
Zurück zum Zitat Bouchardy C, Le MG, Hill C. Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol. 1990;43:267–75.PubMedCrossRef Bouchardy C, Le MG, Hill C. Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol. 1990;43:267–75.PubMedCrossRef
30.
Zurück zum Zitat Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 2010;66:33–8.PubMedCrossRef Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 2010;66:33–8.PubMedCrossRef
31.
Zurück zum Zitat Shields M, Carrol MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS Data Brief. 2011;(56):1–8. Shields M, Carrol MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS Data Brief. 2011;(56):1–8.
32.
Zurück zum Zitat Pisano ED, Hendrick E, Gatsonis CA, et al. Diagnostic accuracy of digital vs film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008;246:376–83.PubMedCrossRef Pisano ED, Hendrick E, Gatsonis CA, et al. Diagnostic accuracy of digital vs film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008;246:376–83.PubMedCrossRef
33.
Zurück zum Zitat Cohen SS, Palmieri RT, Nyante SJ, et al. Obesity and screening for breast, cervical, and colorectal cancer in women. Cancer. 2008;112:1892–904.PubMedCrossRef Cohen SS, Palmieri RT, Nyante SJ, et al. Obesity and screening for breast, cervical, and colorectal cancer in women. Cancer. 2008;112:1892–904.PubMedCrossRef
34.
Zurück zum Zitat Maruthur NM, Bolen S, Brancati FL, Clark JM. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med. 2009;24:665–77.PubMedCrossRef Maruthur NM, Bolen S, Brancati FL, Clark JM. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med. 2009;24:665–77.PubMedCrossRef
35.
Zurück zum Zitat Berclas G, Li S, Price KN, et al.; International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875–84.CrossRef Berclas G, Li S, Price KN, et al.; International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875–84.CrossRef
36.
Zurück zum Zitat Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis among breast cancer patients in Germany—a population based study. Br J Cancer. 2002;86:1034–40.PubMedCrossRef Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis among breast cancer patients in Germany—a population based study. Br J Cancer. 2002;86:1034–40.PubMedCrossRef
37.
Zurück zum Zitat Olson CL, Schumaker HD, Yawn BP. Overweight women delay medical care. Arch Fam Med. 1994;3:888–92.PubMedCrossRef Olson CL, Schumaker HD, Yawn BP. Overweight women delay medical care. Arch Fam Med. 1994;3:888–92.PubMedCrossRef
38.
Zurück zum Zitat Fontaine KR, Faith MS, Allison DB, Cheskin LJ. Body weight and health care among women in the general population. Arch Fam Med. 1998;7:381–4.PubMedCrossRef Fontaine KR, Faith MS, Allison DB, Cheskin LJ. Body weight and health care among women in the general population. Arch Fam Med. 1998;7:381–4.PubMedCrossRef
39.
Zurück zum Zitat Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer. 2008;8:305.PubMedCrossRef Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer. 2008;8:305.PubMedCrossRef
40.
Zurück zum Zitat Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.PubMedCrossRef Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.PubMedCrossRef
41.
Zurück zum Zitat Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in the Nurses Health Study II. Endocr Relat Cancer. 2006;13:583–92.PubMedCrossRef Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in the Nurses Health Study II. Endocr Relat Cancer. 2006;13:583–92.PubMedCrossRef
42.
Zurück zum Zitat Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008;13:16–24.PubMedCrossRef Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008;13:16–24.PubMedCrossRef
43.
Zurück zum Zitat Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol. 2009;27:3271–3.PubMedCrossRef Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol. 2009;27:3271–3.PubMedCrossRef
44.
Zurück zum Zitat Ejlertsen B, Jensen MB, Rank F, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2009;101:729–35.PubMedCrossRef Ejlertsen B, Jensen MB, Rank F, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2009;101:729–35.PubMedCrossRef
45.
Zurück zum Zitat Dhakal HP, Naume B, Synnestvedt M, et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res. 2008;14:2341–50.PubMedCrossRef Dhakal HP, Naume B, Synnestvedt M, et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res. 2008;14:2341–50.PubMedCrossRef
46.
Zurück zum Zitat Garvey PB, Buchel EW, Pockaj BA, Gray RJ, Samson TD. The deep inferior epigastric perforator flap for breast reconstruction in overweight and obese patients. Plast Reconstr Surg. 2005;115:447–57.PubMedCrossRef Garvey PB, Buchel EW, Pockaj BA, Gray RJ, Samson TD. The deep inferior epigastric perforator flap for breast reconstruction in overweight and obese patients. Plast Reconstr Surg. 2005;115:447–57.PubMedCrossRef
47.
Zurück zum Zitat Forouhi P, Dixon JM, Leonard RC, Chetty U. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg. 1995;82:79–82.PubMedCrossRef Forouhi P, Dixon JM, Leonard RC, Chetty U. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg. 1995;82:79–82.PubMedCrossRef
48.
Zurück zum Zitat Vilar-Compte D, Jacquemin B, Robles-Vidal C, Volkow P. Surgical site infections in breast surgery: case-control study. World J Surg. 2004;28:242–6.PubMedCrossRef Vilar-Compte D, Jacquemin B, Robles-Vidal C, Volkow P. Surgical site infections in breast surgery: case-control study. World J Surg. 2004;28:242–6.PubMedCrossRef
49.
Zurück zum Zitat McCarthy CM, Mehrara BJ, Riedel E, et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg. 2008;121:1886–92.PubMedCrossRef McCarthy CM, Mehrara BJ, Riedel E, et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg. 2008;121:1886–92.PubMedCrossRef
50.
Zurück zum Zitat Bozikov K, Arnez T, Hertl K, Arnez ZM. Fat necrosis in free DIEP flaps: incidence, risk, and predictor factors. Ann Plast Surg. 2009;63:138–42.PubMedCrossRef Bozikov K, Arnez T, Hertl K, Arnez ZM. Fat necrosis in free DIEP flaps: incidence, risk, and predictor factors. Ann Plast Surg. 2009;63:138–42.PubMedCrossRef
51.
Zurück zum Zitat Spear SL, Ducic I, Cuoco F, Taylor N. Effect of obesity on flap and donor-site complications in pedicled TRAM flap breast reconstruction. Plast Reconstr Surg. 2007;119:788–95.PubMedCrossRef Spear SL, Ducic I, Cuoco F, Taylor N. Effect of obesity on flap and donor-site complications in pedicled TRAM flap breast reconstruction. Plast Reconstr Surg. 2007;119:788–95.PubMedCrossRef
52.
Zurück zum Zitat Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26:4072–7.PubMedCrossRef Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26:4072–7.PubMedCrossRef
Metadaten
Titel
The Impact of Obesity on Breast Cancer: A Retrospective Review
verfasst von
Danielle J. Haakinson, MD
Steven G. Leeds, MD
Amylou C. Dueck, PhD
Richard J. Gray, MD
Nabil Wasif, MD
Chee-Chee H. Stucky, MD
Donald W. Northfelt, MD
Heidi A. Apsey, CNP
Barbara Pockaj, MD
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2320-8

Weitere Artikel der Ausgabe 9/2012

Annals of Surgical Oncology 9/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.